CA
AKRO

Crewe Advisors’s Akero Therapeutics AKRO Stock Holding History

Crewe Advisors’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-242
Closed -$9.26K – 875
2023
Q1 		$9.26K Hold
242
– – ﹤0.01% 565
2022
Q4 		$13.3K Hold
242
– – ﹤0.01% 496
2022
Q3 		$8K Hold
242
– – ﹤0.01% 709
2022
Q2 		$2K Buy
+242
New +$2.52K ﹤0.01% 956

Other funds holding AKRO

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Crewe Advisors's AKRO Position: Q2 2023 in Review

Crewe Advisors sold out of Akero Therapeutics (AKRO) in Q2 2023, closing a stake of 242 shares — an estimated $9.26K sold.

Crewe Advisors first reported a position in AKRO in Q2 2022 and held it in 4 quarters. The position peaked at $13.3K in Q4 2022. 157 funds tracked by Wall St. Rank hold AKRO as of Q2 2023.

  • Crewe Advisors reported no remaining Akero Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Crewe Advisors sold 242 Akero Therapeutics shares in Q2 2023, an estimated $9.26K.
  • Crewe Advisors first reported a position in Akero Therapeutics in Q2 2022 and held it in 4 quarters.
  • Crewe Advisors's Akero Therapeutics position peaked at $13.3K in Q4 2022.
  • 157 funds tracked by Wall St. Rank held Akero Therapeutics as of Q2 2023.

Based on Crewe Advisors's 13F filing for Q2 2023, filed 28 Jul 2023.